FRLN News and Press, Freeline Therapeutics Holdings plc From 10/09/23

Please find enclosed the presentation in relation to Frontline plc´s investor call to be held on the webcast / conference call October 9, 2023 at 15:00 CET. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. ...

Frontline plc. will host an investor presentation in relation with the announcement «Fully funded acquisition of 24 modern VLCCs from Euronav NV» today, Monday October 9, 2023. A webcast and conference call will be held today at 3:00 p.m. CET (9:00 a.m. U.S. Eastern Time). The presentat...

Frontline plc (“Frontline”) (NYSE and OSE: FRO), today announced that as an integrated solution to the strategic and structural deadlock in Euronav NV (“Euronav”), Frontline has entered into agreements with Euronav to acquire a high-quality ECO fleet of 24 VLCCs with a...

With reference to the stock announcement by Euronav BV (“Euronav”) on 5 October 2023, Frontline plc (“Frontline” or the “Company”) confirms that Frontline, CMB NV (“CMB”) and Euronav, are in discussions on an integrated solution to the strat...

2023-10-05 08:16:47 ET More on BioXcel Therapeutics, Lithium Americas Corp., etc. Lithium Americas (Argentina): An Outrageously Undervalued Lithium Company BioXcel: Navigating The Peaks And Valleys Of Regulatory Uncertainties BioXcel's Struggles: From FDA Issues To F...

2023-10-04 11:45:25 ET More on Freeline Freeline Therapeutics Holdings plc (FRLN) Q2 2023 Earnings Call Transcript Freeline Therapeutics GAAP EPS of -$0.23 beats by $3.28, revenue of $0.62M Seeking Alpha’s Quant Rating on Freeline Therapeutics Historic...

2023-10-04 10:05:42 ET DENVER, Colo., Oct 4, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Siyata Mobile (NASDAQ: SYTA), Vivos Therapeutics (NASDAQ: VVOS), FREYR Battery (NYSE: FREY), Freeline Therapeut...

2023-10-04 09:59:33 ET More on Health Care Select Sector SPDR September Labor Report Preview: Full Employment To Infinity Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Citi turns cautious on pharmaceuticals and biotech BofA Securities:...

2023-10-04 07:57:49 ET (24/7 MARKET NEWS) – Freeline Therapeutics Holdings plc (NASDAQ: FRLN) announced, this morning, positive initial safety, tolerability and enzyme activity data from the ongoing Phase 1/2 GALILEO-1 trial evaluating FLT201, its adeno-associated virus (AAV) gene th...

Robust increases of up to 700-fold over baseline in plasma GCase enzyme activity in first two patients treated with FLT201 Normalization of leukocyte GCase in both patients demonstrates cellular uptake from plasma FLT201 has been well tolerated, with no serious adverse events ...